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Abstract
Background: Over the last years, the number of clinical trials carried out in low-income countries with poor medical
infrastructure and limited access to health care has increased. In these settings, the decision of participating in a
clinical study may be influenced by factors related to participants’ vulnerability that limit the efficacy of the informed
consent.
Methods: A mixed methods social science study, based on the triangulation of qualitative and quantitative data, was
carried out in a socio-economically disadvantaged and semi-urban area of Bobo Dioulasso, Burkina Faso. The study
aimed at assessing the relevance of the informed consent procedure on the decision-making process of the parents
and/or guardians of potential participants in a pediatric malaria trial.
Results: For most parents (70.4%), the decision of participating had already been taken before undergoing the
informed consent process and was based on the information conveyed through the community. Access to free and
good quality health care often inspired this decision. In addition, the parents’ willingness to have their child included
in the trial made them develop active strategies to achieve this purpose.
Discussion: In a context of socio-economic vulnerability and poor access to free health care, the process of
informed consent does not always accomplish its goal of informing people and enabling them to make a free and
informed decision. This information role is somehow anticipated by the community and trial participation becomes a
strategic action to secure otherwise unavailable health resources leading community members to decide on
participation even prior to the informed consent process.
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Introduction
Over the last few years, the number of clinical trials
conducted outside of the European Union [1] and the United
States [2] has significantly increased. This phenomenon has
also occurred in sub-Saharan Africa, partly because of the
need for research addressing local health priorities [3] and
thanks to increased funds for public health-oriented research.
Clinical research is regulated by internationally agreed ethical
principles [4-6] that have been translated into widely accepted
methodological guidelines, national laws and regulations [7,8].
One of these principles, respect for persons, incorporates two
ethical concepts [5], namely (i) individuals should be treated as
autonomous entities, and (ii) persons with diminished
autonomy should be protected. In medical research, the first
concept implies that competent subjects must be free to decide
whether or not to participate in research. It assumes that
competent individuals are able to take an informed decision
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after the informed consent process, in which all relevant
information is provided, discussed and understood. The
concept of diminished autonomy refers to the fact that some
individuals are not considered competent to consent, e.g.
young children [9,10], minors [11–13] or individuals suffering
specific physical/mental conditions [14,15]. In these cases,
additional measures for their protection (i.e. the consent of a
legal representative) must be taken.
Nevertheless, the individual’s willingness and capacity of
taking an unbiased decision on clinical trial participation may
be hampered by other factors, one of them being ‘therapeutic
misconception’, meaning that the distinction between medical
care and medical research is misunderstood [16]. The
individual’s capacity of taking an unbiased decision may also
be limited in medical emergencies [17–19] or when an
individual is desperately ill or has a terminal condition, as the
enrolment in a clinical trial may represent the last hope to
receive a life-saving treatment [20–22].
Diminished power in informed decision-making is not only
linked to individual factors; it can also occur at group or
community level. For instance, certain otherwise competent
groups are potentially vulnerable to exploitation because of
illiteracy [23], institutionalization (e.g. individuals that are part of
highly hierarchical structures such as detainees and/or
soldiers), and socio-economical marginalization or deprivation
[24].
Though some factors limiting the efficacy of the informed
consent process (such as therapeutic misconception) are
ubiquitous, others are more frequent in low-income countries,
such as high illiteracy rates and poor access to good medical
care [25]. In this study the efficacy, strengths and limitations of
the informed consent process, particularly the goal of
voluntariness, were assessed in a clinical trial carried out in a
low-income context.
Methods
Study site and population
This social sciences study was carried out at the Dafra
Health Centre in Bobo Dioulasso, Burkina Faso, among the
parents of children screened and/or recruited in the clinical trial
“In Vivo and in Vitro Efficacy of Antimalarial Treatments in
Children in Burkina Faso” (MALACTRES), aiming at
establishing the efficacy of the two national first-line
antimalarial treatments. The study area is characterized by
informal (i.e. without property titles), semi-urban settlements,
with the furthest households situated approximately 5 km away
from the health center. Economic activities are mostly informal
and include small-scale trading and subsistence farming.
Malaria is the most common cause of hospitalization and death
[26]. Treatment seeking itineraries are mainly based on
medical pluralism, meaning the exploration of a diversity of
therapeutic pathways to recover health. For malaria, self-
medication is often the first recourse. If symptoms persist,
treatment is generally sought at the health centre. Patients
and/or households bear all costs for any of these treatment
choices, translating into a significant financial burden for the
household. In fact, almost half of the population (42.8%) lives
below the poverty line, with a daily income estimated at less
than one$ [27]. The price of a malaria treatment (ASAQ) is
around 0.6$ for an adult, 0.4$ for an adolescent and 0.3$ for a
child, while the costs of attendance at the health facility are of
0.6$ for children and 1.5$ for adults.
The Malactres trial
The Malactres clinical trial (ClinicalTrials.gov identifier:
NCT00808951), to which this social science study was linked,
was a phase IV, open label, parallel group study investigating
the in vivo and in vitro efficacy of artemether-lumefantrine (AL)
and amodiaquine-artesunate (ASAQ) in children with
uncomplicated malaria. It was sponsored by the IRSS/Centre
Muraz (Burkina Faso) and funded by the European Union
(FP7). Children aged 6 months to < 15 years, with mono-
infection with P. falciparum (parasitemia of 4,000–200,000
asexual parasites per µl), fever (axillary temperature ≥ 37.5 °C
or fever in the last 24 hours) and whose parents/guardians
agreed on participation, were eligible to participate. Exclusion
criteria included body weight < 5 kg, haemoglobin < 5.0 g/dl,
participation in any other investigational study during the
previous 30 days, known hypersensitivity to study drugs,
severe malaria, severe malnutrition, as well as other known
intercurrent illness or condition which would place the subject
at risk or interfere with the study results. The primary end-
points were the unadjusted and adjusted treatment failure at
day 42. The secondary end-points were unadjusted and
adjusted treatment failure at day 28, fever clearance time,
asexual parasite clearance time, gametocytaemia at day 7, 14,
21, 28, 35 and 42, and safety profiles. Randomisation numbers
were computer-generated in blocks of 20. Overall, 440 children
were recruited, randomized and treated with either AL or
ASAQ, and actively followed up for 42 days. Recruitment was
carried out during three periods: from December 2008 to
February 2009, from July 2009 to March 2010, and from July to
December 2010. Before the first recruitment period, information
related to the trial had been given to the community inside the
trial area by the research team.
Study design, data collection and sampling
This study triangulated qualitative and quantitative methods
and consisted of three strands, i.e. exploratory, trial and
explanatory (in standard notation [qual → quan+qual → quan],
as described in Figure 1.
The Exploratory Strand consisted of qualitative research in
the local communities.
During the Trial Strand, the qualitative ethnographic data
were triangulated with the quantitative data collected at the
Dafra health center by means of an Entry and Exit Survey for
the parents and/or guardians.
During the Explanatory Strand, a questionnaire was
administered to a random sample of the same parents and/or
guardians.
Exploratory qualitative strand.  In order to explore possible
relevant variables for the second strand of the study, two
months before the start of the third period of recruitment for the
Malactres trial, in-depth interviews were carried out with ten
parents/guardians whose children had been previously
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included in the trial. Parents/guardians were purposefully
sampled (i.e. participants are selected on purpose for the
information they can provide and that could not be obtained as
well from other choices). Informal interviews were also
conducted with fifteen mothers, fathers or guardians whose
children had not been screened for the trial but were aware the
trial was ongoing. Informants were theoretically sampled (i.e.
gradually selected in accordance with emerging results/theory)
at community level. The interviews focused, among other
factors, on knowledge/awareness of the Malactres trial, general
motivations of community members for participating in the trial,
and perceived possible advantages and risks related to the
trial. The in-depth interviews with parents/guardians of
recruited children were recorded and transcribed, while for
parents/guardians of non-recruited children, notes were taken
during or immediately after the informal interviews.
Trial Strand.  The Trial Strand consisted of participant
observation, focus groups discussions and quantitative
surveys.
Participant observation was carried out at the health centre
on a daily basis during the third Malactres recruitment period
and consisted of informal discussions with purposefully
selected parents/guardians attending the health center with
children younger than 15 years old. Informal interviewing was
preferred in order to put the interviewees at ease and reduce
the possible social desirability bias related to the place of the
survey (i.e. health facility) and the type of questions (e.g., the
perception of the trial, the research team and local health staff).
The questions focused on the reasons for attendance, category
of health providers planned to visit, i.e. health staff or research
personnel, and on the knowledge of the trial.
One focus group discussion (FGD) was conducted among
purposefully selected parents/guardians whose children were
screened but not included in the trial. The FGD aimed at
obtaining additional information on the respondents’ opinions
concerning the trial’s inclusion/exclusion criteria. The parents/
guardians were approached after screening, when leaving the
health center. Fourteen people participated in the discussion.
Two brief structured questionnaires were administered at the
health center. The first one (Entry Survey) was administered to
all parents/guardians arriving with a child at the health center. It
consisted of six questions focusing on the reasons for
Figure 1.  Outline of Study Design.  
doi: 10.1371/journal.pone.0080800.g001
attendance, awareness about the ongoing clinical trial and
related expectations.
For the second one (Exit Survey), parent-child pairs were
approached at the time they were leaving the health center.
Parents/guardians whose children had been screened for the
trial were included. The survey consisted of eleven questions
aiming at determining the level of understanding of the
information conveyed during the informed consent process, the
respondents’ reasons for participating, and their knowledge of
the trial’s experimental nature, objectives, risks and benefits.
Explanatory strand.  A follow-up survey was carried out two
months after the end of recruitment on randomly selected
parents/guardians whose children had been screened and who
had agreed to be re-contacted. They were administered a
structured questionnaire (Follow-up Survey), in order to
determine the remaining level of understanding of the trial
objectives and procedures, the overall perception of the trial
and the sources of information on its benefits and risks.
Data analysis
Qualitative data analysis.  Data collection and analysis
were concurrent and data analysis was a continuous, flexible
and iterative process. Preliminary data were intermittently
analyzed in the field after which further research was
conducted confirming or refuting temporary results through
constant validity checks. All transcriptions of recorded
interviews and focus group discussions and the notes of
informal conversations and observations were managed and
analyzed in NVivo 9 (QSR International).
Quantitative data analysis.  All data were entered in
Epidata 3.1 (www.epidata.dk) and analyzed with Stata 11
(www.stata.com). Frequencies were calculated for the main
outcome variables. Fisher’s test was carried out to assess the
role of prior knowledge of the trial on decision to participate.
Data quality and bias.  Given the sensitive nature of the
questions, measures were taken to increase the quality of the
survey data (in terms of wording and question order) as well as
to avoid over-burdening the participants. Qualitative exploratory
data had already shown that parents/guardians did not want to
‘lose time’ at the health center, especially when leaving.
Therefore, socio-demographic information was collected only
during the explanatory strand, within the community, and not at
the health center.
Ethical considerations
The study was approved by the Ethics Committee of the
Centre Muraz (ref.10-2010/CE-CM) and by the Institutional
Review Board of the Institute of Tropical Medicine, Antwerp,
Belgium (ref.10125715). Before fieldwork, local health and
administrative authorities were informed about the study
objectives and the field activities. Ethnographic research
followed the Code of Ethics of the American Anthropological
Association [28]. All interviewees gave oral informed consent
after the explanation of the objectives and procedures in the
local language. Oral consent was preferred and approved by
the above-mentioned committees, since the interviewees were
not put at risk of being harmed in their safety or psychological
well-being. All parents/guardians who were proposed to
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participate gave their consent to do so. All original recordings,
transcriptions and notes were made anonymous. Access to the
database was restricted to the members of the research team.
Results
Overall, 560 parents/guardians participated in the Entry
Survey. Four hundred and eight children met the trial pre-
screening criteria and were asked to complete the Exit Survey
(Trial Strand), 162 of which were recruited for the trial (Table
1). The Follow-up Survey included 112 households, 70 of
which had at least one child included in the trial.
Almost all respondents (98.2%, 110/112) were married,
mostly illiterate women (84%, 94/112 without formal schooling).
Their mean age was 32.7 years (+/- 7.8 SD) (Table 2).
Awareness of the trial upon arrival at health centre
Upon arrival, more than half (62.7%, 351/560) of the
interviewed parents/guardians were already aware of the
ongoing trial (Entry Survey, Table 3). Indeed, 59.7% (334/560)
of them were attending the health centre because of the
research team (referred to as the Centre Muraz team and the
‘people that bring aid’). This proportion was higher (70.4%,
114/162) in the subgroup of parents/guardians of children that
would be later recruited in the trial (Table 4, Exit Survey).
Both the qualitative and quantitative data confirmed that the
information parents/guardians had received on the trial before
meeting the study team came largely from friends and family.
Only 14.3% (16/112) of parents whose children were screened
stated to have heard about the trial for the first time from the
health staff. The content of the information received at
Table 1. Overview Survey participants (Trial Strand).
Phase 2. Trial Phase N Instrument
Caregivers of potential participants attending the
Health Center   
Caregivers of participants not screened by the
research team 152 Entry Survey
Caregivers of participants screened by the research
team 408 Entry + Exit Surveys
Total 560  
Caregivers of participants screened by the
research team   
Caregivers with recruited child(ren) 162 Entry + Exit Surveys
Caregivers with non-recruited child(ren) 225 Entry + Exit Surveys
Caregivers unable or refusal to participate in the
survey 9 Entry + Exit Surveys
Missing 12 Entry + Exit Surveys
Total 408  
Phase 3. Explanatory Phase   
Screened caregivers surveyed in community   
Caregivers with recruited child(ren) 70 Follow-up Survey
Caregivers with non-recruited child(ren) 42 Follow-up Survey
Total 112  
doi: 10.1371/journal.pone.0080800.t001
community level centered mainly on ‘free health care’ and
‘people working on malaria’ and ‘helping children’ (Table 5).
Decision-making
As showed in Table 3, among those parents/guardians
aware of the on-going study upon arrival at the health centre,
the large majority (97.4%, 342/351) had already decided,
before the informed consent procedure, to participate in the
study if the opportunity were offered. Among parents/guardian
who were unaware of the study when arriving at the health
center, a similarly high proportion (85.6%, 178/208) stated they
would participate if any such study was available. More than
half (62.5%) of all parents/guardians was (i) already aware of
the ongoing trial; and (ii) claimed to have attended the health
facility to seek out the research team; and, at the same time,
stated (iii) they had already decided to participate in the trial.
We did the Fisher’s exact test on the role of prior knowledge of
the trial on decision making and the difference was significant
(P<0,001). For (iii), the most common reasons for participation,
as determined in the Exit Survey, were the perceived ‘aid’
provided by the trial (67.3%), the better quality of care (31.5%)
and the better quality of the medication (13.0%) provided
(Table 6).
Perception of the trial in the community
The local communities knew there was a team working on
malaria, perceived to offer aid and free–of-charge treatment.
The research team was often referred to as “les gens qui
aident” (i.e. people providing help) or identified as the ‘Centre
Muraz’s people’, as opposed to the health providers at the
Table 2. Socio-demographic information of the surveyed in
the community (Explanatory Strand).
Mean age (years) Range SD
32.7 20-55 7.8
Socio-demographic information respondents
(Total= 112) Frequency Percentage
Place of residence   
Informal settlement 111 99,1
Other neighbourhoods 1 0,9
Gender   
Female 110 98,2
Male 2 1,79
Level of schooling   
No schooling 94 83,9
Primary 12 10,7
Secondary 6 5,4
Marital status   
Married 110 98,2
Not married 2 1,8
Person accompanying child to the health center   
Mother 102 91, 1
Father 1 0,9
Guardian 9 8
doi: 10.1371/journal.pone.0080800.t002
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health facility where the trial was carried out. Receiving help for
their children was the main motivation for agreeing to
participate in the trial. This aid referred to the free-of-charge
health care and, in a few cases (2.7%), to the ‘taxi money’
(l’argent du taxi) provided as compensation for transport costs.
Similarly, in the follow-up survey, the large majority of
respondents mentioned provision of aid (57.1%) and
improvement of children’s health (21.4%) as the aim of the trial,
while only 10% mentioned that the study compared two
different treatments (Table 7).
Both in the exploratory and trial strands, health care provided
by the research team was perceived as being of better quality
than the one usually available. Taking more time for the clinical
examination, performing diagnostic tests prior to treatment and
providing medication of better quality were among the reasons
given for agreeing to participate in the trial (Table 8, section 3,
Q8-9).
Table 3. Decision making on trial participation of all
caregivers of children attending the health centre (Trial
Strand).
Overview from the Entry Survey Frequency Percentage
Reason for attending the health centre   
To consult the health centre staff 214 38,2
To consult the team of the Centre Muraz 160 28,6
To consult ‘the people that bring aid’ 174 31,1
Don’t know 1 0,18
Other 11 1,97
Total 560 100
Awareness of Malactres Trial   
People attending health centre aware of the trial 351 62,7
Decision to participate upon arrival at the health centre   
Already taken 342 97,4
Not yet decided 4 1,1
Depends 5 1,4
Subtotal 351 100
- People attending health centre not aware of the trial 208 37,1
Intention to participate if asked   
Would participate 178 85,6
Would not participate 17 8,2
Have not decided yet 7 3,4
Do not know 6 2,9
Subtotal 208 100
Missing 1 0,2
Total 560 100
Participants seeking out the trial for participation   
Participants arriving to see Centre Muraz staff; and
aware of The Malactres Trial, and with decision taken
to participate
350 62,5
doi: 10.1371/journal.pone.0080800.t003
Comprehension of research procedures and
therapeutic misconception
Aid.  Despite the explicit mention of ‘research’ in the
informed consent process (Table 8, Q1), the qualitative
analysis of narratives shows that the distinction between aid
and research was often not understood by the respondents and
that people considered the provision of aid, seen as a logical
consequence of their poverty, as the main feature of the trial
(Table 8, section 2, Q6-7).
Randomization.  Despite having the concept of
randomization explained during the informed consent process
(Table 8, section 1, Q3), only 25.3% (41/162) of respondents
had retained that all children did not receive the same
medication during the trial (i.e. two different types of medication
were given to different groups of children). The qualitative
research revealed that even among those who had retained the
information about the use of the two different treatments, it was
believed that the allocation of a specific treatment was the
consequence of the children’s different constitutions and/or
health problems.
Risks and benefits.  During the Exit Survey, only a few
(2.6%, 4/162) parents/guardians stated that there were risks
related to trial participation (Table 6). Conversely, the large
majority (97.5%, 158/162) was able to state trial benefits.
Table 4. Decision making on trial participation of caregivers
of children recruited in the trial (Trial Strand).
Reasons for participation and awareness of the trial Frequency Percentage
Reason for attending the health centre   
To consult the health centre staff 44 27,1
To consult the team of the Centre Muraz 57 35,2
To consult ‘the people that bring aid’ 57 35,2
Don’t know 4 2,5
Total 162 100
Awareness of Malactres Trial   
People attending health centre aware of the trial 118 73
Decision to participate upon arrival at the health centre   
Already taken 117 99,1
Not yet decided 1 0,9
Depends 0 0
Subtotal 118 100
People attending health centre not aware of the trial 44 27,0
Intention to participate if asked   
Would participate 41 93,0
Would not participate 3 7,0
Subtotal 44 100
Total 162 100
Participants seeking out the trial for participation   
Participants (i) arriving to see Centre Muraz staff; and,
(ii) aware of The Malactres Trial, and (iii) with decision
taken to participate in trial.
114 70,4
doi: 10.1371/journal.pone.0080800.t004
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However, only few (10.5%) affirmed that the trial could cause
discomfort to the child or that the medication could have side
effects (6.2%).
Confidentiality.  Only 1 person (1/162) (Table 6) had
retained any information about the right to confidentiality,
despite the fact that this was explained in the informed consent
process.
Withdrawing from the study.  Two respondents (2/162)
(Table 6) had retained they could withdraw from the study at
any time (Table 8, section 1, Q4-5).
Informal enrolment strategies
Qualitative data from the Exploratory and Trial Strands
showed that community members were not passive
participants, rather active actors in the trial enrolment process,
to the extent of developing strategies to increase the chances
of their child being included in the trial. These strategies
included providing erroneous information to the study team,
e.g. not declaring the treatment taken by the child before
attendance or not reporting non-malaria symptoms such as
coughing or colds or other complications. Other strategies
consisted in attending the health center very early in the
morning; or, situating oneself in a clearly visible position in the
waiting room to be more easily noticed by the trial staff (as
some days not all potential patients could be screened); or
sending someone else to assure such a place in the waiting
room; and, trying to negotiate inclusion through an
acquaintance of a member of the trial team.
The large majority (86%, 60/70) of parents/guardians of
recruited children carefully stored their signed informed
consent form, even after the end of trial, as evidence of trial
Table 5. Descriptive analysis of the Follow-up Survey
(Explanatory Strand).
Sources and content of the information leading to
decision making Frequency Percentage
Reported source of initial information on the trial   
Neighbors 67 59,8
Health staff 16 14,3
Relatives 5 4,5
Other 13 11,6
Missing 11 9,8
Total 112 100
Reported content of the information initially
provided   
People providing free care 39 34,8
People working on malaria 31 27,7
People helping children 25 22,3
Clinical trial with medicines 1 0,9
Taxi money as benefit 3 2,7
Missing 13 11,6
Total 112 100
doi: 10.1371/journal.pone.0080800.t005
participation (Table 7). This is per se good practice, but proving
previous trial participation was generally believed to give the
Table 6. Descriptive analysis of Exit Survey response (Trial
Strand).
Overview of the Exit Survey after the informed
consent process Frequency Percentage
Reasons to have accepted to participate in the trial
(multiple responses)   
Aid provided by the trial 109 67,3
Better quality of care 51 31,5
Better quality of the medication 21 13,0
Other 3 1,9
Knowledge of the reasons behind the study   
Yes 8 4,9
No 154 95,1
Total 162 100
Knowledge of the benefits of the trials   
Able to mention trial benefits 158 97,5
Unable to mention trial benefits 4 2,5
Total 162 100
Knowledge of the possible risks for the child   
Yes 4 2,6
No 152 97,4
Missing 6  
Total 162 100
Knowledge of the difference in medication for the
children in the study   
Yes 82 50,6
No 41 25,3
Don’t know 39 24,1
Total 162 100
Knowledge of the possible discomforts of the
medication   
Yes 17 10,5
No 115 71,0
Don’t know 30 18,5
Total 162 100
Knowledge of the possible negative effects of the
medication   
Yes 10 6,2
No 105 64,8
Don’t know 47 29,0
Total 162 100
The trial team mentioned that the personal
information is confidential   
Yes 1 0,6
No 161 99,4
Total 162 100
doi: 10.1371/journal.pone.0080800.t006
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Table 7. Descriptive analysis of the Follow-up Survey
responses of caregivers of children recruited in the trial
(Trial Strand).
Overview topics from the Follow-up Survey Frequency Percentage
Aim of the trial according to participants   
To compare different medication 7 10,0
To improve the child’s health 15 21,4
Providing aid 40 57,1
Do not know 8 11,4
Total 70 100
Children experiencing problems during trial   
Yes 0 0
No 70 100
Total 70 100
Awareness of possibility of leaving trial   
Yes 2 3
No 68 97
Total 70 100
Considering drop-out during the trial   
Yes 0 0
No 70 100
Total 70 100
Person signing the informed consent form   
Mother 63 90,0
Father 3 4,3
Other 3 4,3
Missing 1 1,4
Total 70 100
Literacy   
Illiterate (not able to read) 9 12,9
Literate (able to read) 60 85,7
Missing 1 1,4
Total 70 100
Obtaining more information on consent from
relatives   
Yes 6 8,6
No 64 91,4
Total 70 100
Still have the informed consent form   
Yes 60 85,7
No 10 14,3
Total 70 100
Received money from research team   
Yes 70 100
No 0 0
Total 70 100
Use of ‘taxi money’   
Food 63 90,0
Article of clothing 15 21,4
Transport 1 1,4
former participants a higher chance of enrolment in future trials
or to allow them to benefit from free-of-charge routine health
care after the trial.
Discussion
The process of informed consent translates the ethical
principle of respect for persons into practice and is founded on
three main principles, namely information, comprehension and
voluntariness [5]. Patients and/or their parents or guardians
should be provided with clear, complete and balanced
information on the proposed clinical trial so that they can freely
decide on their participation. Failing to do so would open the
door to potential abuse and malpractice. Nevertheless, besides
the information received during the consent process, other
factors can influence the patient’s or parent’s decision. Clearly,
in the low-income setting where this study was carried out,
most parents were aware of the ongoing trial and wanted their
child to be enrolled before having received any information
from the research team; rather, based on the information
circulating in their community. This means that the decision to
participate in the trial preceded the informed consent process,
and was not necessarily dependent on the type and quality of
the information provided by the study team, with the risk of
biasing the consent process. This does not necessarily imply
that the information provided during the informed consent
process was inconsequential in influencing decision-making as
it could have helped the parents confirm their pre-existing
intentions. It is, nevertheless, clear that such decisions were
often guided by additional factors and motives unrelated to the
trial’s purposes, e.g. free and better quality health care and
reimbursement of travel expenses.
Another element potentially biasing the informed consent
procedure was the lack of understanding of trial procedures
among potential participants or their parents/guardians. Only a
small percentage of parents retained key aspects of the trial
Table 7 (continued).
Overview topics from the Follow-up Survey Frequency Percentage
Care 1 1,4
Total 70 100
Perception of Centre Muraz (multiple options)   
Institution providing aid 50 71,4
Institution providing health care 13 18,6
Institution providing free-of-charge health care 5 7,1
Research institution 2 2,9
Total 70 100
Perception of Centre Muraz (forced choice)   
Institution providing aid 65 92,9
Institution providing health care 67 95,7
Institution providing free-of-charge health care 59 84,3
Research institution 21 30,0
Total 70 100
doi: 10.1371/journal.pone.0080800.t007
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procedures (i.e. main research aim, randomization, and the
right to confidentiality) even when the questions were asked
immediately after the informed consent procedure. It is possible
that the apparent lack of understanding could be less of a
problem of comprehension than of voluntariness or free
decision-making, as it can be partially due to participants’ lack
Table 8. Quotes illustrating qualitative findings (Exploratory
and Trial Strands).
1. Key Information conveyed during informed consent process
Q1. This is research study is being done to learn more about the treatment of
malaria. We are carrying out a research study to compare different medicines for
the treatment of mild malaria (Malactres Patient Information Sheet).
Q2. With this study we want to find out their efficacy and safety and also see if he
parasite is resistant to them (Malactres Patient Information Sheet).
Q3. The study medicine that your child will receive will be determined by a process
of randomization. Randomization means that your child will receive by a study
nurse one of the 2 medicines studied by chance (Malactres Patient Information
Sheet).
Q4. Your child’s participation in this study is completely voluntary. If you decide
that you do not want to participate in the study or decide to withdraw your child
from the study at any time and for any reason, this will not affect your child’s care
at the outpatient department, where standard care for all medical problems is
available. During the study, you will be informed promptly of any new information
that may influence your willingness to continue participation in the study.
Q5. Should you decide to withdraw your child from the study before your child has
finished the course of study medicines, then your child will receive the local
standard treatment for malaria from the study team, but after the standard
treatment has been given, medical care will no longer be provided by the study
team. If the child is withdrawn from the study after completion of the course of
study medicines, then no further care will be provided by the study team (Malactres
Patient Information Sheet).
2. Research as Aid
Q6. People know we are poor, so they help us’ [Interview participating mother]
Q7. The doctors know that we do not have the money to treat our children so they
treat them free of charge’. [Interview participating mother]
3. REPORTED REASONS FOR TRIAL PARTICIPATION
Q8. The doctors of the Centre Muraz take the child’s blood and check if he really
has malaria while the others only ask what is wrong with the child’ [Informal
conversation with participating mother].
Q9. When the other doctors give my children medication, two days later the
disease starts again. That’s why I wanted the team of Muraz to treat him” [Informal
conversation with participating mother].
4. Strategies for trial enrolment
Q10. When I got to the health centre, I didn’t know I shouldn’t have told the doctors
that I had already given some medication to my child. Had I known that they
refused to enrol my child for that I would never have told them” [Interview with
mother of a non-recruited child].
5. Perception of the trial in The community
Q11. I had received information on the work from women who came from the
health centre with their children. They told me that someone was treating children
free-of-charge’ [FGD. Mother of a non-recruited child]
Q12. I heard women say that there were people at the health centre who treat
children free-of-charge, so I went’ [Informal conversation with mothers of recruited
children].
doi: 10.1371/journal.pone.0080800.t008
of interest in understanding the trial procedures in relation to
the offered and/or perceived benefits. In addition, the clinical
trial was a low-risk study as the study treatments corresponded
to the recommended first line treatments, possibly explaining
the little concern parents/guardians had over the potential risks.
Parents’/guardians’ attitude towards a trial with a potentially
higher risk, e.g. a phase II trial, may be different.
In Burkina Faso, user-fees are required for malaria diagnosis
and treatment, with no waiver for special categories of patients
such as children under 5 years of age or pregnant women.
Accordingly, malaria treatment can constitute a considerable
financial strain for low-income households, especially during
the malaria season. The provision of free-of-charge care as
well as the accurate follow-up offered to the child after initial
treatment made study participation attractive, to the point that
70,4% of the parents of recruited children had actively tried to
have their child included in the trial. These factors imply a
different way of interpreting trial participants’ role, namely as
people acting upon the availability of the trial and not as
passive participants being guided through an informed consent
process. However, while practices such as early morning
attendance to the health centre or trying to negotiate inclusion
through an acquaintance in the clinical trial team would not
increase the individual risk, providing erroneous information on
previous symptoms, including those of severe malaria, may do
so. The question remains whether the informed consent
process in this setting fully achieves its objectives.
The common and understandable wish of potential trial
participants to be recruited in a clinical trial to benefit of the
service offered, particularly for the socio-economically
disadvantaged households, leads to a need for improved
strategies to make the informed consent process more
effective. This, however, is more easily said than done as the
research team provided extensive information (in the local
language) on the research and answered any questions the
parents/guardians may have asked.
The reputation of/trust in the research team and the
perception of aid probably played a major role in decision-
making. It is obvious that if the population had not trusted the
research team, the recruitment and follow-up rate would have
been much lower than observed. Nevertheless, the desire to
secure otherwise unavailable good quality health care should
not overshadow the fact that children were included in a
research project, and not in a humanitarian program, even
despite the low risk of the trial.
In conclusion, in a context characterized by socio-
economical vulnerability and poor access to free health care,
the process of informed consent does not always accomplish
its goal of enabling potential study participants to make a free
and informed decision. This information role is somehow
anticipated by the community and trial participation may
become a strategic action to secure otherwise unavailable
health resources leading community members to decide on
participation even prior to the informed consent process. Given
the direct benefits of trial participation and possible trust in
researchers, innovative strategies to ensure a free decision-
making process are required.
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